
Howard McLeod Highlighted The Results of the Phase II Randomized LEANOX Trial
Howard McLeod, Center Director at Center for Precision Medicine & Functional Genomics, shared a post on LinkedIn:
“Details matter in cancer therapy! Use of lean body mass, rather then total body mass, for Oxalaplatin chemotherapy resulted in similar relapse free survival, but much less peripheral neuropathy! Precision oncology doesn’t just mean fancy genomics or such.”
Title: Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial
Authors: Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou, Hervé Perrier, Faiza Khemissa Akouz, Romain Desgrippes, Marie-Pierre Galais, Chloé Janiszewski, Thibault Mazard, Yves Rinaldi, Côme Lepage, Raphael Tetreau, Pierre Senesse
Read the Full Article.
Read more posts on Colon Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023